Nine pathways, no composite score
Each finding stays in its own pathway. Adding them into one number would hide what is actually informative.
Whole-genome sequencing costs a few hundred dollars and every published association can be queried in seconds, yet genomic information has been glacially slow to reach clinical practice. At PLC we treat a patient's genome as a modern adjunct to a detailed history. This tool shows how, using the markers consumer arrays already test, for cardiovascular risk and its management.
Fifty markers, nine pathways.LDL, Lp(a), triglycerides, cholesterol absorption, artery wall, blood pressure, rhythm, and how you handle statins and clopidogrel.
Works with 23andMe-style text files, AncestryDNA files, CSV, TSV, and selected single-sample SNP VCF files.
If your download is a .zip or .gz, open it first and choose the DNA file inside.Seeing the report for your own file needs a free Google sign-in. We keep your name and email, never your DNA file or results. The fictional sample needs no sign-in.Highly penetrant variants can change management outright; APOE status is one example. Most findings are more nuanced, and we fold them into Bayesian decision-making when choosing between essentially equal options. If your genetics suggest you retain salt, hydrochlorothiazide may reasonably be the first antihypertensive we try, assuming nothing else points elsewhere.
Each finding stays in its own pathway. Adding them into one number would hide what is actually informative.
Which statin, whether to add ezetimibe, which first antihypertensive, whether clopidogrel will work.
Each finding carries the physiology, an evidence label, the primary sources and the exact DNA calls behind it.
Each pathway asks a different question about cholesterol, blood vessels, heart rhythm, or medicine handling.